Could depression be treated with Botox?

In the largest randomized, double-blind, placebo controlled study to date on the effect of OnabotulinumtoxinA (as known as Botox) on depression, researchers found that more than half of subjects suffering from moderate to severe depression showed a substantial improvement (greater than or equal to 50% of baseline) in their depressive symptoms as measured by the MADRS scale.

The study, conducted by Dr. Eric Finzi, MD, PhD and Dr. Norman E. Rosenthal, MD and published in the Journal of Psychiatric Research, included 74 depressed subjects injected with a single treatment of either onabotulinumtoxinA (OBA) or a placebo to the corrugator and procerus muscles between the eyebrows. Results showed that (as assessed by the MADRS scale) in the OBA treatment group decreased 47 percent after six weeks, compared to 21 percent in the placebo group. This study is the first to show a significant difference in remission rate with OBA in depressed patients (27% OBA vs. 7% ).

Study co-author Dr. Norman E. Rosenthal, MD, Clinical Professor of Psychiatry at Georgetown Medical School, commented, "This research is groundbreaking because it offers those who suffer from and their doctors an entirely new approach to treating the condition - one that doesn't conflict with any other treatments."

The study showed that Botox may help relieve depressive symptoms both as a stand-alone and an adjunctive treatment.

"This new research supports earlier facial feedback theory of Charles Darwin and William James which suggests that facial expressions influence mood," added Dr. Eric Finzi, Dermasurgeon and co-author on the paper that first reported that inhibition of frowning by facial injection of OBA could help depressed patients in a pilot study published in 2006.

More information: This article "Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial" by Eric Finzi and Norman E. Rosenthal, is published in Journal of Psychiatric Research, Volume 52 (May 2014). dx.doi.org/10.1016/j.jpsychires.2013.11.006

add to favorites email to friend print save as pdf

Related Stories

Varenicline helps smokers with depression to quit smoking

Sep 16, 2013

About half of smokers seeking treatment for smoking cessation have a history of depression. Compared with smokers who are not depressed, those who suffer from a major depressive disorder (MDD) have greater difficulty quitting.

Recommended for you

Family dinners reduce effects of cyberbullying in adolescents

4 hours ago

Sharing regular family meals with children may help protect them from the effects of cyberbullying, according to a study by McGill professor Frank Elgar, Institute for Health and Social Policy. Because family meal times represent ...

The Edwardians were also fans of brain training

10 hours ago

Brain-training programmes are all the rage. They are part of a growing digital brain-health industry that earned more than US$1 billion in revenue in 2012 and is estimated to reach US$6 billion by 2020. The extent to which they actually improve brain function re ...

Report advocates improved police training

Aug 29, 2014

A new report released yesterday by the Mental Health Commission of Canada identifies ways to improve the mental health training and education that police personnel receive.

User comments